Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa
暂无分享,去创建一个
Evan Wood | Paula Braitstein | Martin T Schechter | R. Hogg | J. Montaner | M. Schechter | P. Braitstein | E. Wood | M. Tyndall | M. O’Shaughnessy | Julio SG Montaner | Robert S Hogg | Mark W Tyndall | Michael V O'Shaughnessy | M. O'shaughnessy | M. O'Shaughnessy | E. Wood
[1] R. Hogg,et al. Modern Antiretroviral Therapy Improves Life Expectancy of Gay and Bisexual Males in Vancouver’s West End , 2000, Canadian journal of public health = Revue canadienne de sante publique.
[2] S. Spector,et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. , 1998, The Journal of infectious diseases.
[3] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[4] M. Fowler,et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. , 2000, JAMA.
[5] G. Gray,et al. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa , 1999, BMJ.
[6] R. Hogg,et al. One world, one hope: the cost of providing antiretroviral therapy to all nations , 1998, AIDS.
[7] L. Gilson,et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania , 1997, The Lancet.
[8] J. Phair. Determinants of the natural history of human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.
[9] B. Yip,et al. Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.
[10] James G. Kahn,et al. Cost‐effectiveness of antiviral drug therapy to reduce mother‐to‐child HIV transmission in sub‐Saharan Africa , 1998, AIDS.
[11] Julio S. G. Montaner,et al. Antiretroviral medication use among injection drug users: two potential futures , 2000, AIDS.
[12] J. Karon,et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial , 1999, The Lancet.
[13] Dorothy Bray,et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.
[14] L. Mofenson,et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). , 1999, AIDS.
[15] R. Hogg,et al. HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials. , 1996, AIDS.
[16] F. Onyango,et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. , 2000, JAMA.
[17] New public/private sector effort initiated to accelerate access to HIV/AIDS care and treatment in developing countries. , 2000, International journal of epidemiology.
[18] Elliot Marseille,et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa , 1999, The Lancet.
[19] H. Gershengorn,et al. A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.
[20] R. Hogg,et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.
[21] P. Vernazza,et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV , 2000, AIDS.
[22] J. Curran,et al. Science, ethics, and future of research into maternal-infant transmission of HIV-1 , 1999, The Lancet.
[23] E. Vittinghoff,et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. , 1999, The Journal of infectious diseases.
[24] F. Mmiro,et al. HIVNET nevirapine trials , 1999, The Lancet.
[25] R. Salamon,et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial , 1999, The Lancet.
[26] F. Dabis,et al. Acceptability of voluntary HIV testing by pregnant women in developing countries: an international survey , 1998, AIDS.
[27] R. Pollard,et al. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. , 1998, Clinical therapeutics.
[28] J. Stover,et al. Projecting the impact of AIDS on mortality. , 1998, AIDS.
[29] J. Gallant,et al. Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.